{"id":"agn-199201-dose-c","safety":{"commonSideEffects":[{"rate":null,"effect":"Unknown"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"The exact mechanism of action of AGN-199201 Dose C is not well understood, but it is believed to work by interacting with the molecular target to produce a therapeutic effect.","oneSentence":"AGN-199201 Dose C is a drug that targets the molecular target to exert its therapeutic effect.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T03:20:22.092Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Phase 2 clinical trials for AGN-199201 Dose C are ongoing, but no specific indications have been reported."}]},"trialDetails":[{"nctId":"NCT02595528","phase":"PHASE2","title":"A Study of the Concurrent Use of AGN-190584 and AGN-199201 in Participants With Presbyopia","status":"COMPLETED","sponsor":"Allergan","startDate":"2016-04-29","conditions":"Presbyopia","enrollment":163},{"nctId":"NCT02780115","phase":"PHASE2","title":"A Safety, Efficacy and Pharmacokinetic Study of AGN-199201 and AGN-190584 in Patients With Presbyopia","status":"COMPLETED","sponsor":"Allergan","startDate":"2016-05-26","conditions":"Presbyopia","enrollment":151},{"nctId":"NCT01735201","phase":"PHASE2","title":"AGN-199201 for the Treatment of Erythema With Rosacea","status":"COMPLETED","sponsor":"Allergan","startDate":"2012-12","conditions":"Rosacea, Erythema","enrollment":357}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":557,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"AGN-199201 Dose C","genericName":"AGN-199201 Dose C","companyName":"Allergan","companyId":"allergan","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AGN-199201 Dose C is a drug that targets the molecular target to exert its therapeutic effect. Used for Phase 2 clinical trials for AGN-199201 Dose C are ongoing, but no specific indications have been reported..","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}